(Q39396267)

11 September 2017

title

Inhibition of metadherin sensitizes breast cancer cells to AZD6244. (English)

1 reference

11 September 2017

Xiaoli Kong

1

1 reference

11 September 2017

Meena S Moran

series ordinal

2

1 reference

11 September 2017

Yuhan Zhao

series ordinal

3

1 reference

11 September 2017

Qifeng Yang

series ordinal

4

1 reference

11 September 2017

publication date

1 January 2012

1 reference

Cancer Biology and Therapy

11 September 2017

published in

1 reference

11 September 2017

volume

13

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

43-49

1 reference

Global health inequalities and breast cancer: an impending public health problem for developing countries

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Breast cancer metastasis: markers and models

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Prediction of drug response in breast cancer using integrative experimental/computational modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Therapy of breast cancer with molecular targeting agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Molecular targeted therapies for breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

The complexity of mitogen-activated protein kinases (MAPKs) made simple

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Immunohistochemical analysis of Metadherin in proliferative and cancerous breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and regulates TLR4 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.13.1.18868

21 January 2018

Identifiers

DOI

10.4161/CBT.13.1.18868

1 reference

11 September 2017

1 reference